Loading...
XHKG
1110
Market cap42mUSD
Jul 18, Last price  
0.57HKD
1D
-3.39%
1Q
16.33%
Jan 2017
-53.66%
IPO
-77.20%
Name

Kingworld Medicines Group Ltd

Chart & Performance

D1W1MN
No data to show
P/E
7.40
P/S
0.29
EPS
0.07
Div Yield, %
5.93%
Shrs. gr., 5y
-1.48%
Rev. gr., 5y
1.65%
Revenues
1.06b
-1.63%
556,417,000638,046,000685,562,000705,519,000554,763,000660,323,000713,548,0001,053,527,0001,031,488,0001,078,843,000977,928,000745,383,000847,386,000957,701,0001,078,659,0001,061,082,000
Net income
42m
+9.08%
37,244,00042,863,00051,031,00048,535,00047,177,00037,865,00031,205,00046,966,00051,060,00041,005,00043,427,00050,889,00051,211,00043,542,00038,096,00041,557,000
CFO
0k
-100.00%
158,647,00013,416,000-53,326,00073,203,000-49,849,000-5,230,000102,790,000-2,207,00072,388,00062,385,000132,711,000123,584,00081,199,000186,548,00042,284,0000
Dividend
Jun 05, 20250.0317 HKD/sh

Profile

Kingworld Medicines Group Limited, an investment holding company, distributes branded imported pharmaceutical and healthcare products. The company also supplies pharmaceutical, healthcare, general foodstuffs, and medical products. It offers products for various functional categories, such as cough and phlegm relieving, gastrointestinal, vitamin, orthopedics, cardiovascular, influenza, and other categories under the Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and Mentholatum Product Range brands. The company also manufactures and sells electrotherapeutic and physiotherapeutic devices, and general medical examination devices. It serves in the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and internationally. The company was founded in 1996 and is headquartered in Shenzhen, the People's Republic of China.
IPO date
Nov 25, 2010
Employees
1,019
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,061,082
-1.63%
1,078,659
12.63%
957,701
13.02%
Cost of revenue
997,725
1,039,128
900,618
Unusual Expense (Income)
NOPBT
63,357
39,531
57,083
NOPBT Margin
5.97%
3.66%
5.96%
Operating Taxes
21,053
32,292
24,042
Tax Rate
33.23%
81.69%
42.12%
NOPAT
42,304
7,239
33,041
Net income
41,557
9.08%
38,096
-12.51%
43,542
-14.98%
Dividends
(13,921)
(13,292)
Dividend yield
3.73%
2.51%
Proceeds from repurchase of equity
(10,074)
BB yield
1.90%
Debt
Debt current
230,020
198,029
279,291
Long-term debt
187,238
168,693
30,776
Deferred revenue
600
Other long-term liabilities
22,751
Net debt
286
20,688
(65,910)
Cash flow
Cash from operating activities
42,284
186,548
CAPEX
(105,535)
(92,913)
Cash from investing activities
(120,634)
(84,049)
Cash from financing activities
4,372
(51,311)
FCF
75,454
(103,330)
38,980
Balance
Cash
249,601
194,029
256,167
Long term investments
167,371
152,005
119,810
Excess cash
363,918
292,101
328,092
Stockholders' equity
705,532
575,632
549,777
Invested Capital
766,802
761,677
640,086
ROIC
5.54%
1.03%
5.08%
ROCE
5.60%
3.69%
5.80%
EV
Common stock shares outstanding
575,919
591,627
622,500
Price
0.46
-27.78%
0.63
-25.88%
0.85
11.84%
Market cap
262,043
-29.70%
372,725
-29.56%
529,125
11.84%
EV
328,069
473,731
585,464
EBITDA
63,357
59,606
95,275
EV/EBITDA
5.18
7.95
6.14
Interest
11,519
12,292
Interest/NOPBT
29.14%
21.53%